Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Proteimax Bio Technology Israel Ltd. has a single pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is confined to 1 distinct art unit and 1 distinct examiner, HIBBERT, CATHERINE S. As the busiest examiner with 1 pending case, HIBBERT, CATHERINE S holds the entirety of the company's current active examination volume.
The presence of only 1 pending office action suggests a highly specific or early-stage portfolio. Because there is only 1 distinct examiner involved, the company's immediate prosecution success is tied to 1 point of review. This allows the applicant to dedicate all resources to the 1 pending office action. The involvement of only 1 distinct art unit further simplifies the prosecution landscape. Practitioners can focus exclusively on the standards and precedents relevant to the 1 distinct examiner currently assigned to the file. This relationship between the pending action and the examiner facilitates a clear and focused dialogue during the examination process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264174 | ADDITIVE FOR PRESERVING CELLS, TISSUE AND/OR FOOD | HIBBERT, CATHERINE S | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264174 | ADDITIVE FOR PRESERVING CELLS, TISSUE AND/OR FOOD | HIBBERT, CATHERINE S | 1658 | §103 | Final Rejection | — | Pending | Aug 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProteimax Bio Technology Israel Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Catherine S Hibbert has the most, with 1 of Proteimax Bio Technology Israel Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.